①固态电池+宁德时代概念+钠离子电池+氟化工！这家公司已获得固态电池原材料硫化锂相关专利且正 在推动产业化；②人形机器人+无人驾驶+特斯拉！这家公司已与众多头部机器人企业开展业务合作且 业务已初具规模；③固态电池+机器人+低空经济+华为！公司签署协议拟就固态锂电材料等产品展开合 作，现阶段固态电池材料出货近50吨。（2家主板、1家创业板公司） 前言 ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global innovative pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for producing high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 26, the company's stock price fell by 2.02%, with a trading volume of 64.12 million yuan and a turnover rate of 3.17%, bringing the total market capitalization to 4.272 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 8.2 million yuan on the day [5][6]. Technical Analysis - The average trading cost of the stock is 39.14 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [7]. - The stock price is approaching a resistance level of 36.40 yuan, indicating potential for a pullback unless this level is broken [7].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for the production of high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, a year-on-year increase of 32.98%, and a net profit attributable to the parent company of 71.76 million yuan, a year-on-year increase of 123.61% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 25, the company's stock price increased by 0.08%, with a trading volume of 84.12 million yuan and a turnover rate of 4.07%, bringing the total market capitalization to 4.36 billion yuan [1]. - The main net inflow of funds today was 6.39 million yuan, with no significant trend in the main force's position [5][6]. Technical Analysis - The average trading cost of the stock is 39.25 yuan, with recent rapid outflows of chips, suggesting a potential recommendation for portfolio adjustment [7].

Core Viewpoint - The company JinKai Life Science has shown a positive market performance with a 1.46% increase in stock price, reaching a market capitalization of 4.357 billion yuan, while its main business focuses on providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [1][8]. Business Overview - The company's main business involves providing custom R&D and production services for small molecule drug intermediates and a limited amount of raw materials for global innovative pharmaceutical companies [2][8]. - JinKai's primary products include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant focus on Alzheimer's-related intermediates and has established capabilities in fluorination processes [3][4]. Financial Performance - For the first half of 2025, JinKai achieved a revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, which is a 123.61% increase compared to the previous year [8]. - The company's overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Market Activity - The stock has experienced a net outflow of 2.1341 million yuan from major investors today, indicating a trend of reduced holdings over the past three days [5][6]. - The average trading cost of the stock is 39.38 yuan, with the current price approaching a resistance level of 36.40 yuan, suggesting potential for upward movement if this level is surpassed [7]. Shareholder Information - As of September 19, the number of shareholders in JinKai decreased by 3.65% to 14,300, with an average of 3,968 circulating shares per person, reflecting a slight increase of 3.78% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Institutional Holdings - As of June 30, 2025, two major funds exited the top ten circulating shareholders list, indicating potential shifts in institutional interest [10].

金融工程 证 券 研 究 报 告 市场情绪监控周报（20250908-20250912） 本周热度变化最大行业为电力设备、房地产 本周概念热度变化最大的 5 个概念为赛马概念、氟化工概念、PVDF 概念、广 东自贸区、有机硅概念。 ❖ 本周市场估值跟踪 本周宽基和行业估值： 沪深 300、中证 500、中证 1000 的滚动 5 年历史分位数分别为 85%、99%、 93%。 申万一级行业中，从 2015 年开始回溯，当前估值处于历史分位数 80%以上的 一级行业有：电力设备、电子、计算机、轻工制造、医药生物、国防军工、银 行、商贸零售、建筑材料、传媒、煤炭、基础化工；位于估值历史 20%以下的 有食品饮料、非银金融、交通运输、综合、钢铁； 申万二级行业中，从 2015 年开始回溯，目前处于历史分位数 80%以上的二级 行业有化学制药、航天装备、冶钢原料、生物制品、国有大型银行、风电设备、 半导体、一般零售、环保设备、航空机场、服装家纺、元件、汽车服务、商用 车、旅游及景区、橡胶、装修建材、房地产服务、专业连锁、动物保健、多元 金融、化学纤维、光学光电子、广告营销、特钢、其他电子、电子化学品、玻 璃玻纤。 ❖ ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and custom R&D production services for new drug development projects [2][8]. - The company has launched projects for pharmaceutical intermediates, including the oral formulation absorption enhancer SNAC for Semaglutide [2][3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On September 4, the company's stock price decreased by 0.28%, with a trading volume of 170 million yuan and a turnover rate of 7.65%, resulting in a total market capitalization of 4.66 billion yuan [1]. - The stock has seen a net inflow of 7.47 million yuan from major investors today, with no significant trend in major holdings [5][6].

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., specializes in providing custom research and development services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and custom R&D production services for new drug development projects [2][8]. - The company has launched projects for pharmaceutical intermediates, including the production of Semaglutide oral formulation absorption enhancers [2][3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the first half of 2025, the company achieved revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On August 28, the company's stock price fell by 1.21%, with a trading volume of 225 million yuan and a turnover rate of 9.93%, resulting in a total market capitalization of 4.83 billion yuan [1]. - The stock has seen a net outflow of 12.15 million yuan from major investors today, with a continuous reduction in major funds over the past three days [5][6]. Group 4: Technical Analysis - The average trading cost of the stock is 42.20 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [7]. - The current stock price is near a support level of 40.00 yuan, which is critical for potential rebound or further decline [7].

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., specializes in providing custom research and development services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of August 20, 2023, the company reported a revenue composition of 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. - The company has a significant overseas revenue share, accounting for 61.18%, benefiting from the depreciation of the Renminbi [4]. Financial Performance - For the first half of 2025, the company achieved a revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, which is a 123.61% increase year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On August 26, 2023, the company's stock price fell by 2.63%, with a trading volume of 301 million yuan and a turnover rate of 12.27%, resulting in a total market capitalization of 5.137 billion yuan [1]. - The stock has seen a net outflow of 16.28 million yuan from major investors, indicating a reduction in holdings over the past two days [5][6]. Technical Analysis - The average trading cost of the stock is 42.50 yuan, with the current price approaching a resistance level of 42.97 yuan, suggesting potential for a price correction if this level is not surpassed [7].

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., is engaged in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business segments include fluorinated CDMO services (69.58% of revenue) and non-fluorinated CDMO services (29.10%), with minor contributions from trade and technical services [8]. - The company has a significant overseas revenue share of 61.18%, benefiting from the depreciation of the Chinese yuan [4]. Recent Developments - As of August 8, 2023, the company is involved in projects related to the production of intermediates for Semaglutide oral formulations [2]. - The company also provides intermediates for Alzheimer's-related drugs to biopharmaceutical companies in Europe and the U.S. [3]. Financial Performance - For the first quarter of 2025, the company reported a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit of 47.42 million yuan, up 183.24% year-on-year [8]. Market Activity - On August 15, 2023, the company's stock price increased by 1.05%, with a trading volume of 127 million yuan and a turnover rate of 5.95%, leading to a total market capitalization of 4.542 billion yuan [1]. - The stock has seen a net outflow of 7.42 million yuan from major investors, indicating a reduction in holdings over the past two days [5][6]. Technical Analysis - The average trading cost of the stock is 39.15 yuan, with the current price approaching a resistance level of 38.05 yuan, suggesting potential for a price correction if this level is not surpassed [7]. Shareholder Information - As of August 8, 2023, the number of shareholders decreased by 4.76% to 13,700, with an average of 4,136 circulating shares per person, which increased by 4.99% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business segments include fluorinated CDMO services (69.58% of revenue) and non-fluorinated CDMO services (29.10%), with minor contributions from trade and technical services [8]. - The company has a significant overseas revenue share of 61.18%, benefiting from the depreciation of the Chinese yuan [4]. Recent Developments - As of August 8, 2023, the company is involved in projects related to the production of intermediates for Semaglutide oral formulations [2]. - The company also provides intermediates for Alzheimer's-related projects for biopharmaceutical companies in Europe and the United States [3]. Financial Performance - For the first quarter of 2025, the company reported a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit of approximately 47.42 million yuan, up 183.24% year-on-year [8]. Market Activity - On August 14, 2023, the company's stock price fell by 4.41%, with a trading volume of 254 million yuan and a turnover rate of 11.80%, resulting in a total market capitalization of approximately 4.495 billion yuan [1]. - The stock has shown no clear trend in major capital inflows, with a net outflow of 10.79 million yuan on the day [5][6]. Technical Analysis - The average trading cost of the stock is 39.26 yuan, with the current price approaching a resistance level of 38.05 yuan, indicating potential for a price correction if this level is not surpassed [7].